Allergan's Assets Could Diversify Pfizer's Neurology Portfolio
This article was originally published in Scrip
If Pfizer Inc. were to buy Allergan plc – or vice versa – the merged companies would have a large and actually quite diverse portfolio of drugs for central nervous system (CNS) diseases and conditions.
You may also be interested in...
Allergan PLC has $27.6m in cash after closing the $40.5bn sale of its generics business to Teva Pharmaceutical Industries Ltd. and paying down $9.3bn debt, but the company will rely on blockbuster sales gains and recent launches for revenue and earnings growth, not a big acquisition.
CEO Amit Munshi told the J.P. Morgan meeting the company will double the size of its clinical-stage cardiovascular disease pipeline with the addition of temanogrel.
Lilly took a different path to positive results in Alzheimer’s with a smaller, biomarker-driven study to test the hypothesis that rapid, robust clearance of amyloid could slow disease progression, CEO David Ricks explains at J.P. Morgan.